



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Friday, November 27, 2009

Clingenix Incorporated

[View the current Clingenix Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/484-Clingenix+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/484-Clingenix+Incorporated.html>)

Contact Details:

1190 Bordeaux Drive

Sunnyvale

CA

94089

United States of America

Tel: (408) 752-1635

Fax: (408) 752-0347

Email: dgessner@clingenix.com

Clingenix, Inc. was founded in 1998 by leading scientists from Harvard, Stanford, and private industry to provide pharmacogenomic as well as conventional research, development and application services to the drug development and medical device industries. The founders are experts in the fields of medicine, genetics, clinical trials, and information technology. The Company is headquartered in Sunnyvale, California with operations through out the US, Taiwan and the Asia Pacific Region. The company provides a full range of services from developmental consulting, through all phases of clinical development, to commercialization. The mission of the Company is to be the premiere pharmacogenomics company offering a full range of genomic based research, development and application services and diagnostic products for monitoring diseases and disease progression to pharmaceutical, biotechnology, medical device, and diagnostic companies for drug development and commercialization.

Clingenix provides pharmacogenomics services and diagnostic products in the therapeutic areas of diabetes, insulin resistance, hypertension, oncology, cardiovascular and atherosclerosis. The company is currently expanding to other therapeutic areas using the initial template.

Clingenix's management believes that the application of pharmacogenomics knowledge coupled with traditional discovery and developmental processes to drug development will reduce clinical trial costs, shorten the drug development cycle, improve new drugs approval rate and market positioning, rescue drugs that will or have failed clinical trial or FDA approval, and improve trial predictability. These outcomes are possible because

pharmacogenomics allows for better targeting, higher efficacy, and lower toxicity of new drugs.

The Company services provide for many commercial advantages in medicine, and diagnostics. Clingenix enjoys a decisive market advantage over its competitors through existing capabilities in Asia. Advantages include extensive access to investigators and patients, ownership of biological materials from type 2 diabetes, ownership of a database in the insulin resistant and hypertension therapeutic areas, and world renown technical expertise in these therapeutic areas. The database contains genotype, phenotype, and metabolic data, total genome scan with over 300 markers, and immortal cell lines. Putative loci linked to resistance and dyslipidemia have also been identified.

Clingenix collaborates with academic and industrial leaders in pharmaceuticals, diagnostics, biotechnology, and medical instrumentation.

Based on a strong foundation in medicine, genomics, clinical trials, and information technology, Clingenix promises to be the premiere provider of pharmacogenomics services and products.

Press Releases on Clingenix Incorporated:

Reportlinker Adds Blood Banking and Blood Products - Global Market Perspective	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Blood Banking and Blood Products - Global Market Perspective http://www
Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference	24th November, 2009	Quest Diagnostics	MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is
Prodesse's ProParafu+(TM) Assay Cleared for US Marketing by FDA	24th November, 2009	Gen-Probe Incorporated	Michael Watts Vice president, investor relations and corporate communications 858-410-8673 SOURCE Gen-Probe Incorporated
Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio	24th November, 2009	Aflac Incorporated	COLUMBUS, Ga., Nov. 24 /PRNewswire-FirstCall/ -- Aflac Incorporated (NYSE: AFL) announced today that the Lloyds Banking Group plc has accepted the exchange of two of its investment securities owned by
WellTek Positioned to Capitalize on Trends in Health and Fitness	24th November, 2009	WellTek Incorporated	ORLANDO, Fla., Nov. 24 /PRNewswire-FirstCall/ -- Two thirds of adults are overweight and one third of those are obese. Experts estimate that 80 percent of the population will experience a back

BioNews Results for Clingenix Incorporated



- [Synteract Expands Executive Roles to Aid International Growth New hire and promotions follow opening of Prague](#)
Pharma Live: Nov 2 2009 2:41PM Matching: clingenix
- [People on the move: pharma outsourcing jobs](#)
Outsourcing Pharma: Nov 2 2009 2:37PM Matching: clingenix
- [Synteract Expands Executive Roles to Aid International Growth](#)

- Pharma Live: Oct 30 2009 6:10PM Matching: clingenix*
- [Synteract Expands International Roles](#)
Contract Pharma: Oct 29 2009 10:07PM Matching: clingenix
 - [Synteract Expands Executive Roles to Aid International Growth](#)
Pharmacy Choice: Oct 27 2009 3:32AM Matching: clingenix
 - [Contract Research Organization, Synteract, opens office in Prague](#)
Pharma Live: Oct 26 2009 7:41PM Matching: clingenix
 - [Synteract Expands Executive Roles to Aid International Growth](#)
Street Insider: Oct 26 2009 4:32PM Matching: clingenix
 - [Synteract Expands Executive Roles to Aid International Growth](#)
Earthtimes.org: Oct 26 2009 4:25PM Matching: clingenix

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,

